Nationwide Children’s gene therapy spinoff acquired for $100M

Yet another gene therapy spinoff from Nationwide Children’s Hospital has been acquired for $100 million.

Celenex is developing a treatment for Batten Disease, a rare, fatal neurological condition that causes blindness and progressive loss of speech and movement. Children who inherit it typically don’t live past age 12.

Click here to read the complete article.

Story excerpt provided by Columbus Business First.

Written by Carrie Ghose.

Originally published September 21, 2018.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: